| HOME >> BIOLOGY >> TECHNOLOGY |
Britain's University of the Year Announces Potential Breakthrough in the
Fight Against Hepatitis C.
CHICAGO, Sept. 17 /PRNewswire/ -- The British Midlands Development Corporation today announced that the University of Nottingham in the British Midlands has released a statement promoting the development of a possible Hepatitis C Vaccine.
The United Kingdom is home to Europe's largest biotechnology sector, generating revenues in excess of $8.6 billion per year. In central England is the British Midlands region, which is at the heart of the UK's biopharma and medical device industries.
The British Midlands is one of Europe's premier locations for the advancement of medicine and life sciences. All of the region's 18 universities have unique areas of scientific expertise, which fuel the region's record of innovation in the field.
Some of the twentieth century's most important innovations in medicine took shape in the British Midlands. Magnetic resonance imaging (MRI) was invented by The University of Nottingham's Sir Peter Mansfield. The Birmingham Children's Hospital leads the field in treatments for congenital heart disease and developed the world's smallest successful heart pacemaker in a three-day old infant.
Just last week, another potential breakthrough was announced by the British Midlands' University of Nottingham, which released a statement claiming the discovery of a possible vaccine which can be used in the treatment of Hepatitis C.
Dr. Alexander Tarr, a Research Fellow at Nottingham's Institute of Infection, Immunity and Inflammation, presented a paper titled 'Human Antibodies to Hepatitis C Virus - Potential for Vaccine Design', at the Society for General Microbiology's 161st meeting which was held at The University of Edinburgh two weeks ago.
The research group had recently analyzed antibodies that can
successfully prevent infection with many diverse strains of Hepatitis C
virus in l
'/>"/>
| SOURCE The British Midlands Development Corporation Copyright©2007 PR Newswire. All rights reserved |